BRAF 測試市場：市場規模（按細分市場）、份額、監管、報銷、預測（~2033 年）

黑色素瘤在全球最常見的惡性腫瘤中排名第 19 位，估計年齡標準化發生率為每 10 萬人 2.8 至 3.1 例。 各國之間的發病率差異很大，其中澳洲發病率最高（每 10 萬人 37 例），中亞和南亞發病率最低（每 10 萬人 0.2 例）。 這些模式是由於種族不同的皮膚表型差異以及世界各地陽光照射的差異所造成的。 引起皮膚黑色素瘤的基本環境因素是紫外線。

大腸癌 (CRC) 是男性第三大常見癌症，女性第二常見癌症。 據世界衛生組織 (WHO) 稱，2018 年報告了約 180 萬新發結直腸癌病例。 肺癌是第二常見的癌症，2018 年報告的肺癌新病例約 200 萬例。 吸菸是所有年齡層肺癌的主要危險因素，全世界約 80% 的男性肺癌病例和 45% 的女性肺癌病例可歸因於吸菸。

BRAF 基因為製造將特定訊號從細胞外傳遞到細胞核的蛋白質提供了指導。 該蛋白是 RAF/MAPK 訊號通路的一部分，該通路控制多種重要的細胞功能。 特別是，RAF/MAPK 路徑指導細胞發育和分裂（增殖）、細胞發育成特定功能（分化）、細胞運動（遷移）和細胞破裂（凋亡）的步驟。 透過此途徑的化學訊號傳導是典型產前發育的基礎。

BRAF檢測包括BRAF免疫組織化學（IHC）、BRAF桑格定序、BRAF核酸擴增檢測（NAAT）、BRAF其他檢測（BRAF原位雜交（ISH）、質譜陣列檢測）。

本報告深入探討了全球 BRAF 測試市場，包括競爭格局、SWOT 分析、到 2033 年的市場預測、COVID-19 的影響以及區域和國家趨勢。Masu。

目錄

目前BRAF測試的市場及競爭狀況

• 對主要產業趨勢的見解
• 2015 年至 2033 年 BRAF 測試按細分市場劃分的市場總收入和市場前景
• 有關數量、平均售價和市場價值的詳細數據

全球、區域與國家見解

• BRAF測試市場的SWOT分析
• BRAF 測試市場的競爭動態洞察與趨勢
• 各國醫療保健系統概覽
• 按國家/地區劃分的報銷政策
• 各國醫療科技的監管狀況

Abstract

BRAF Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on BRAF Tests market for the year 2020 and beyond. Melanoma is accounted for as the nineteenth most basic malignant growth around the world, with assessed age-standardized frequency rates of 2.8-3.1 per 100,000. There is significant variety in frequency between nations, with the highest rates seen in Australia (37 for every 100,000) and the least in South-Central Asia (0.2 per 100,000). This pattern is ascribed to varieties in racial skin phenotype, just as contrasts in sun exposure around the globe. The fundamental environmental factor causing cutaneous melanoma is UV radiation.

Colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in women. Approximately 1.8 million new CRC incident cases were reported in 2018, according to the World Health Organization. Lung cancer is the second most common cancer with approximately 2.0 million new cases of lung cancer reported in 2018. Cigarette smoking is the dominant risk factor associated with lung cancer across all age groups, with approximately 80% of male and 45% of female lung cancer cases worldwide attributed to smoking.

The BRAF gene gives guidelines to making a protein that transmits specific signals from outside the cell to the cell's nucleus. This protein is a piece of a signaling pathway known as the RAF/MAPK pathway, which controls a few significant cell functions. In particular, the RAF/MAPK pathway directs the development and division (proliferation) of cells, the procedure by which cells develop to specific functions (differentiation), cell movement (migration), and the implosion of cells (apoptosis). Chemical signaling through this pathway is basic for typical development before birth.

The BRAF tests include BRAF Immunohistochemistry (IHC), BRAF Sanger sequencing, BRAF Nucleic Acid Amplification Tests (NAATs) and BRAF other Tests (BRAF In Situ Hybridization (ISH), Mass Array Tests).

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed BRAF Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total BRAF Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for BRAF Tests market.
• Competitive dynamics insights and trends provided for BRAF Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: F. Hoffmann-La Roche Ltd, bioMerieux SA, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, Takara Bio Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, Biocartis Group NV, BGI Genomics Co Ltd, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the BRAF Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on BRAF Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving BRAF Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BRAF Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific BRAF Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable